GSK Highlights R&D Productivity Gains In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.
You may also be interested in...
Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.
Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.
Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.